Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
31 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
ActogeniX NV - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'ActogeniX NV - Product Pipeline Review - 2014', provides an overview of the ActogeniX NV's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of ActogeniX NV's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of ActogeniX NV including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of ActogeniX NV's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the ActogeniX NV's pipeline products Reasons to buy - Evaluate ActogeniX NV's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of ActogeniX NV in its therapy areas of focus - Identify new drug targets and therapeutic classes in the ActogeniX NV's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of ActogeniX NV and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of ActogeniX NV - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of ActogeniX NV and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 ActogeniX NV Snapshot 5 ActogeniX NV Overview 5 Key Information 5 Key Facts 5 ActogeniX NV - Research and Development Overview 6 Key Therapeutic Areas 6 ActogeniX NV - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 ActogeniX NV - Pipeline Products Glance 12 ActogeniX NV - Clinical Stage Pipeline Products 12 Phase I Products/Combination Treatment Modalities 12 ActogeniX NV - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Discovery Products/Combination Treatment Modalities 14 ActogeniX NV - Drug Profiles 15 AG-013 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 AG-014 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Cell Therapy for Allergic Disease 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Cell Therapy for Type 2 Diabetes 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Genetically Engineered Bacteria for Celiac Disease 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Genetically Engineered Bacteria for Type 1 Diabetes 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Cell Therapy for Undisclosed Indication 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Genetically Engineered Bacteria For Clostridium Difficile Enteropathy 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 ActogeniX NV - Pipeline Analysis 23 ActogeniX NV - Pipeline Products by Target 23 ActogeniX NV - Pipeline Products by Route of Administration 24 ActogeniX NV - Pipeline Products by Molecule Type 25 ActogeniX NV - Pipeline Products by Mechanism of Action 26 ActogeniX NV - Recent Pipeline Updates 27 ActogeniX NV - Dormant Projects 28 ActogeniX NV - Locations And Subsidiaries 29 Head Office 29 Appendix 30 Methodology 30 Coverage 30 Secondary Research 30 Primary Research 30 Expert Panel Validation 30 Contact Us 31 Disclaimer 31
List of Tables ActogeniX NV, Key Information 5 ActogeniX NV, Key Facts 5 ActogeniX NV - Pipeline by Indication, 2014 7 ActogeniX NV - Pipeline by Stage of Development, 2014 8 ActogeniX NV - Monotherapy Products in Pipeline, 2014 9 ActogeniX NV - Partnered Products in Pipeline, 2014 10 ActogeniX NV - Partnered Products/ Combination Treatment Modalities, 2014 11 ActogeniX NV - Phase I, 2014 12 ActogeniX NV - Preclinical, 2014 13 ActogeniX NV - Discovery, 2014 14 ActogeniX NV - Pipeline by Target, 2014 23 ActogeniX NV - Pipeline by Route of Administration, 2014 24 ActogeniX NV - Pipeline by Molecule Type, 2014 25 ActogeniX NV - Pipeline Products by Mechanism of Action, 2014 26 ActogeniX NV - Recent Pipeline Updates, 2014 27 ActogeniX NV - Dormant Developmental Projects,2014 28
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.